FDA Approves GSK's Jemperli for Advanced Rectal Cancer
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
GSK announced that the U.S. Food and Drug Administration approved Jemperli (dostarlimab). The approval is for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway. Dr. Andrea Cercek of Memorial Sloan Kettering Cancer Center noted that results from the AZUR-1 trial demonstrate potential for a fundamentally different treatment approach in this patient group.
From investegate.co.uk
Why it matters
The approval provides a new immunotherapy option for a subset of rectal cancer patients, potentially allowing them to avoid standard treatments like chemotherapy, radiation, and surgery. This validates Jemperli's commercial viability and introduces a new therapeutic standard for MSI-H/dMMR tumors.
From investegate.co.uk
Who's involved
- GSKPharmaceutical company that received FDA approval for Jemperli
- Memorial Sloan Kettering Cancer CenterCancer treatment institution involved in the AZUR-1 clinical trial
- FDARegulatory agency that granted accelerated approval to Jemperli
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- GSKSpeculative
GSK could see increased revenue and market share due to the new drug's regulatory approval and market access.
Keep exploring
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company
-
Memorial Sloan Kettering Cancer Center
cancer treatment and research institution in New York City, United States
- Estée Lauder's Chairman supports cancer research, and Larry Norton is named founding scientific director at Memorial Sloan Kettering.
- Prelude Corporation's genomic test has been adopted in various US centers and is driving clinical decision-making, affiliated with Memorial Sloan Kettering Cancer Center.
- FDA